Articles that tag KARD but are mainly about other companies.
Tonlamarsen (ASO targeting angiotensinogen) demonstrated statistically significant reduction in plasma AGT levels and clinically meaningful blood pressure reduction in Phase II KARDINAL trial, supporting advancement to Phase IIb.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
